United Therapeutics Corporation Proceeds from Sale and Maturity of Marketable Securities
United Therapeutics Corporation (UTHR) reported Proceeds from Sale and Maturity of Marketable Securities of $36.20 million for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2011-02-24
- United Therapeutics Corporation proceeds from sale and maturity of marketable securities for the quarter ending 2010-12-31 was $0.00.
- United Therapeutics Corporation proceeds from sale and maturity of marketable securities for the quarter ending 2010-09-30 was $19.02M, a 10771.43% increase year-over-year.
- United Therapeutics Corporation proceeds from sale and maturity of marketable securities for the quarter ending 2009-09-30 was $175.00K.
- United Therapeutics Corporation proceeds from sale and maturity of marketable securities for fiscal 2010 was $36.20M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-24 | $19.02M derived: sum of 2 quarters · filed 2011-02-24 | $36.20M 10-K · filed 2011-02-24 | |
| 2010-09-30 | $19.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $36.20M 10-Q · filed 2010-10-28 | ||
| 2010-06-30 | $17.18M 10-Q · filed 2010-07-28 | |||
| 2009-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $225.00K 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $50.00K 10-Q · filed 2010-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |